TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02265055

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transfer early cleavage embryos
Description: transfer early cleavage embryos

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transfer non early cleavage embryo
Study: NCT00446147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridoxine
Description: 100mg BID/daily, Per oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo 100mg BID/daily, Per oral
Study: NCT02660320

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dermabrasion
Description: Preparing the graft bed before epidermal cell suspension The epidermis can be removed using ablative CO2 or Erbium laser. We will assess the efficacy of using instead micro-needles to create micro-holes that will allow the melanocytes to reach the lower layers of the epidermis and thus repigment the lesional skin.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Laser placebo
Description: The epidermis can be removed using ablative CO2 or Erbium laser. We will assess the efficacy of using instead micro-needles to create micro-holes that will allow the melanocytes to reach the lower layers of the epidermis and thus repigment the lesional skin.
Study: NCT00266305

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fish oil (Dry n-3, BASF)
Description: 5 g/oil daily for the first four month of lactation
Study: NCT05211128

Intervention type: PROCEDURE
Intervention: Robotic Surgery
Description: Surgical procedure using robotic technologies.

Intervention type: PROCEDURE
Intervention: Robotic Surgery
Description: Surgical procedure using robotic technologies.

Intervention type: PROCEDURE
Intervention: Robotic Surgery
Description: Surgical procedure using robotic technologies.

Intervention type: PROCEDURE
Intervention: Robotic Surgery
Description: Surgical procedure using robotic technologies.

Intervention type: PROCEDURE
Intervention: Open Surgery
Description: Surgical procedure using a large, open cut in the skin.

Intervention type: PROCEDURE
Intervention: Open Surgery
Description: Surgical procedure using a large, open cut in the skin.

Intervention type: PROCEDURE
Intervention: Open Surgery
Description: Surgical procedure using a large, open cut in the skin.

Intervention type: PROCEDURE
Intervention: Open Surgery
Description: Surgical procedure using a large, open cut in the skin.

Intervention type: PROCEDURE
Intervention: Laparoscopic Surgery
Description: Surgical procedure using small incisions and trochars.

Intervention type: PROCEDURE
Intervention: Laparoscopic Surgery
Description: Surgical procedure using small incisions and trochars.

Intervention type: PROCEDURE
Intervention: Laparoscopic Surgery
Description: Surgical procedure using small incisions and trochars.

Intervention type: PROCEDURE
Intervention: Laparoscopic Surgery
Description: Surgical procedure using small incisions and trochars.
Study: NCT01200797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SJG-136
Description: Given IV
Study: NCT00266305

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Fish oil (Dry n-3, BASF)
Description: 5 g/oil daily for the first four month of lactation
Study: NCT01248715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oseltamivir
Description: These patients will receive early (within 8-12 hours of admission, no later than 24 hours after admission) oseltamivir plus current, standard empiric antibacterial therapy based on national recommendations from the IDSA/ATS guidelines for management of hospitalized patients with CAP (2). Anti-influenza therapy will be given using oseltamivir at a dose of 75 mg twice daily. The oseltamivir dose will be adjusted in patients with renal insufficiency according to the package insert. Duration of antiviral therapy will be for a minimum of 5 days for patients with evidence of early clinical improvement and prolonged depending on clinical stability
Study: NCT03665714

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Impact Oral
Description: Impact Oral belongs to Food for Special Medical Purpose (FSMP) according to China registration regulation, including Omega-3 fatty acids, Arginine and Nucleotides immunonutrition.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Impact Oral
Description: Impact Oral belongs to Food for Special Medical Purpose (FSMP) according to China registration regulation, including Omega-3 fatty acids, Arginine and Nucleotides immunonutrition.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enteral Nutrition Emulsion(TPF-T)
Description: TPF-T

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enteral Nutrition Emulsion(TPF-T)
Description: TPF-T
Study: NCT01200797

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01644175

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for alirocumab)
Description: Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector (also known as pre-filled pen).
Study: NCT02377648

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Everolimus-Eluting Bioresorbable Vascular Scaffold (ABSORB)
Description: Placement of bioresorbable vascular scaffold in presence of at least one critical angiographic de novo lesion (DS ≥70%) or a non-critical angiographic de novo lesion (50% ≤ DS \<70%) associated with concomitant signs or symptoms of myocardial ischemia.
Study: NCT02632487

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Center-based walking + balance, stretching, and light resistance

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Center-based walking + balance, stretching, and light resistance
Study: NCT03270839

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kwells
Description: Motion sickness drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kwells
Description: Motion sickness drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: No active substance in the tablet
Study: NCT02632487

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-Exercise Physical Activity (NEPA)
Description: Behavioral counseling paired with technology intervention to monitor physical activity
Study: NCT03270839

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: No active substance in the tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: No active substance in the tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: No active substance in the tablet
Study: NCT03748719

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: SBRT treatment
Study: NCT01839149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TI-001
Description: TI-001 is intranasal oxytocin
Study: NCT00674739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: daily topical application for up to 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3.75% imiquimod cream
Description: 3.75% imiquimod cream applied daily to wart areas for up to 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo cream
Description: placebo cream applied daily to wart areas for up to 8 weeks
Study: NCT00154154

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Psychiatric Management
Description: General Psychiatric Management (GPM) condition consisting of a structured algorithmic medication intervention plus psychosocial counseling.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behaviour Therapy
Description: Modification of behaviours achieved with reframing thoughts and impulses
Study: NCT03980652

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Change of gloves and sterile instruments
Description: Change of gloves and use of separate , sterile instruments before closing the abdominal wall
Study: NCT03108131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Given PO
Study: NCT03106324

Intervention type: DRUG
Intervention: Revlimid (lenalidomide)
Description: Treatment with first line Revlimid containing regimen as prescribed in routine clinical practice

Intervention type: DRUG
Intervention: Revlimid (lenalidomide)
Description: Treatment with first line Revlimid containing regimen as prescribed in routine clinical practice
Study: NCT00657189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-545
Description: 100 mg once; SC Placebo × 12 doses on other weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-545
Description: 100 mg every 4 weeks × 4 doses; SC Placebo × 9 doses on other weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-545
Description: 100 mg every 2 weeks × 7 doses; SC Placebo × 6 doses on other weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-545
Description: 100 mg every week × 13 doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC Placebo every week × 13 doses
Study: NCT01482312

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon A contact lenses
Description: Commercially marketed, silicone hydrogel, single-vision, soft contact lenses FDA-approved for daily and extended (overnight) wear for up to 30 nights of continuous wear.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon A contact lenses
Description: Commercially marketed, silicone hydrogel, single-vision, soft contact lenses FDA-approved for daily and extended (overnight) wear for up to 30 nights of continuous wear.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon A contact lenses
Description: Commercially marketed, silicone hydrogel, single-vision, soft contact lenses FDA-approved for daily and extended (overnight) wear for up to 30 nights of continuous wear.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A contact lenses
Description: Commercially marketed, silicone hydrogel, single-vision, soft contact lenses FDA-approved for daily and extended (overnight) wear for up to 30 nights of continuous wear.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A contact lenses
Description: Commercially marketed, silicone hydrogel, single-vision, soft contact lenses FDA-approved for daily and extended (overnight) wear for up to 30 nights of continuous wear.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A contact lenses
Description: Commercially marketed, silicone hydrogel, single-vision, soft contact lenses FDA-approved for daily and extended (overnight) wear for up to 30 nights of continuous wear.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glasses
Description: Glasses per habitual prescription

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glasses
Description: Glasses per habitual prescription

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glasses
Description: Glasses per habitual prescription
Study: NCT03106675

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal ablation of bone metastasis with MR-HIFU device Philips Sonalleve coupled with Philips Ingenia 3.0T
Description: Procedure is performed under proper analgesia (general or local anesthesia). The intervention can be performed in areas accessible with ultrasound with no critical structures (nerves, vasculature, bowels) in proximity. Limbs and pelvis are most usually accepted locations.~Patient is adjusted on top of the HIFU-transducer connected to MRI. First a MR-scan is performed and the treatment procedure is planned on consol. Then under MRI-guidance a point by point ablation of the target tumor is performed. During the treatment a real-time thermometry is obtained in order to avoid unwanted heating of related structures and to observe sufficient effect on treatment zone. After treatment MR-scan with gadolinium is performed to evaluate the size of ablated area.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Varian Truebeam Radiotherapy System
Description: Conventional radiotherapy focused on bone tumor. Pretreatment planning images acquired with computer tomography
Study: NCT02665156

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracorporeal stapled neobladder using robotic staplers
Description: Robot assisted radical cystecomy. Separate packages extended pelvic lymph node dissection up to aortic bifurcation. Totally intracorporeal orthotopic ileal neobladder with about 45 cm of ileum according to Vescica Ileal Padovana.
Study: NCT00811967

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PegIntron (peginterferon alfa-2b; SCH 54031)
Description: PegIntron administered at a dose of 1.5 ug/kg QW SC for up to 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebetol (ribavirin; SCH 18908)
Description: Rebetol administered at a dose of 600, 800, or 1000 mg/day, orally, for up to 48 weeks.
Study: NCT02235454

Intervention type: DEVICE
Group type: OTHER
Intervention: SDOCT-GMPE software
Description: Noninvasive imaging of the optic nerve in patients with existing glaucoma
Study: NCT04016519

Intervention type: OTHER
Intervention: Gastrostomie
Description: Gastrostomy involves creating an opening between the skin and the stomach. It allows the administration of nutrition solutes or food directly into the stomach without passing through the mouth and esophagus. It is a method widely used since the 1980s for enteral nutrition.~In the field of pediatrics, gastrostomy is considered in chronic diseases when enteral nutrition is necessary in the long term.
Study: NCT01839149

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01252030

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: physical activity monitors
Description: physical activity monitors

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No physical activity monitors
Description: No physical activity monitors
Study: NCT02682082

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic ultrasound-guided celiax plexus neurolysis
Description: Endoscopic ultrasound-guided celiax plexus neurolysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound-guided celiax plexus neurolysis
Description: Endoscopic ultrasound-guided celiax plexus neurolysis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Endoscopic ultrasound-guided celiax plexus neurolysis w/wo Bupivacaine
Study: NCT01586221

Intervention type: OTHER
Group type: OTHER
Intervention: Music & Physical Therapy
Description: Participants will receive combined Music Therapy and Physical Therapy for 6 Weeks. Two times per week for 1 hour.
Study: NCT03406117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAT1
Description: All the participants will have the test product applied to the appropriate test sites by trained study staff. The study was conducted on a mixed population comprising of normal subjects, and patients with atopic dermatitis and active plaque psoriasis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAT1
Description: All the participants will have the test product applied to the appropriate test sites by trained study staff. The study was conducted on a mixed population comprising of normal subjects, and patients with atopic dermatitis and active plaque psoriasis.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline Solution
Description: Only for CIT portion of the study. Participant will have product applied topically on site by the trained study staff.
Study: NCT01870726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC280
Description: Phase Ib: INC280 was given at the starting dose of 200mg capsules twice daily with escalation to higher strengths.~Phase II: INC280 was given at the dose of 400mg (tablets) twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC280
Description: Phase Ib: INC280 was given at the starting dose of 200mg capsules twice daily with escalation to higher strengths.~Phase II: INC280 was given at the dose of 400mg (tablets) twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buparlisib
Description: Buparlisib was given at the starting dose of 50mg once daily with escalation to higher strengths.
Study: NCT01452581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Red blood cell transfusion
Description: Maximal 2 units of packed red blood cells given one at a time on the first postoperative day. Evaluation of primary outcome is done after administration of each unit.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Voluven
Description: Infusion of up to 2 x 280 ml colloid (6% Hydroxyethyl Starch 130/0.4 in 0.9% Sodium Chloride). 280 ml at a time. Evaluation of primary outcome after each intervention.
Study: NCT01644175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector (also known as pre-filled pen).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipid-Modifying Therapy (LMT)
Description: Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lipid-Modifying Therapy (LMT)
Description: Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
Study: NCT01822132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended release naltrexone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04328831

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: IBI322
Description: Recombinant anti-human CD47/PD-L1 bispecific antibody injection
Study: NCT04100707

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Genicular block was applied
Description: This procedure is performed with ultrasound and / or fluoroscopy, sterile staining and covering of painful knee to the middle of thigh and leg, localization of superomedial, superolateral, inferomedial genicular nerves are tested and then conventional radiofrequency is applied to all 3 nerve regions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Genicular block was applied
Description: This procedure is performed with ultrasound and / or fluoroscopy, sterile staining and covering of painful knee to the middle of thigh and leg, localization of superomedial, superolateral, inferomedial genicular nerves are tested and then conventional radiofrequency is applied to all 3 nerve regions
Study: NCT04684147

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: single dose of CNCT19
Description: Dose: 0.5 x 10\^8 CNCT19 Cell Injection via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide
Study: NCT01542385

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stent
Description: Percutaneous coronary intervention: reperfusion with a thrombectomy catheter or a small balloon angioplasty catheter, followed by coronary stenting

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stent
Description: Percutaneous coronary intervention: reperfusion with a thrombectomy catheter or a small balloon angioplasty catheter, followed by coronary stenting
Study: NCT04249258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dobutamine
Description: Dobutamine will then be administered at doses of 5mcg/kg/min, 10mcg/kg/min, 15mcg/kg/min and 20mcg/kg/min.
Study: NCT04601545

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary rehabilitation
Description: Three weeks of pulmonary rehabilitation conducted in an outpatient care facility:~* 5- time a week for 30 minutes a specific respiratory exercises- relaxation exercises for breathing muscles, exercises to increase breathing, prolonged exhalation exercise, chest percussion~* 5- time a week for 20-30 min training on a cycle ergometer - until the Heart Rate reaches 60% of the HRmax~* 5- time a week for 30 minutes a fitness and respiratory exercises - coordination and balance exercises, stretching exercises~* relaxation by Schultz Autogenic Training. The technique involves the daily practice of sessions that last around 15 minutes. During each session, the practitioner repeats a set of visualisations that induce a state of relaxation.
Study: NCT02102854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rATG
Description: Infusion of horse or rabbit-derived antibodies against human T cells, used to prevent \& treat acute rejection in organ transplantation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rATG
Description: Infusion of horse or rabbit-derived antibodies against human T cells, used to prevent \& treat acute rejection in organ transplantation
Study: NCT04443972

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PD VitalOs cement®
Description: PD VitalOs cement®\* is a synthetic bone grafting cement designed for bone void filling and bone regeneration in dental surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PD VitalOs cement®
Description: PD VitalOs cement®\* is a synthetic bone grafting cement designed for bone void filling and bone regeneration in dental surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite bone graft
Description: a bioceramic bone substitute, providing a scaffold for bone deposition

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biodegardable collagen membrane
Description: provide efficacious barriers that were interposed between the flap and root surface.
Study: NCT02198937

Intervention type: OTHER
Intervention: Blood sample

Intervention type: OTHER
Intervention: Blood sample
Study: NCT04601545

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual therapeutic support
Description: 8 sessions of VR therapy (each of them 20 minutes long). As a virtual reality source, VR Tier One device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VR therapy provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach. The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the therapist tells the patient a symbolic story about his/her situation.~By performing tasks in the virtual garden, the patient becomes an active participant of the therapeutic process and sees the effects his/her work.